Volume 14, Number 3—March 2008
Research
Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands
Jakko van Ingen*†
, Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†
, Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†
Table 1
Baseline population characteristics of 49 patients with nontuberculous mycobacterial infection, the Netherlands, January 1999 through March 2005*
| Characteristic | ATS+ (n = 25) | ATS– (n = 24) | Total (%) |
|---|---|---|---|
| Demographics | |||
| Male sex | 19 | 18 | 37 (76) |
| Mean age, y | 60 | 60 | 60 |
| Dutch origin |
24 |
20 |
44 (90) |
| Concurrent and predisposing conditions | |||
| Pre-existing pulmonary disease | 21 | 18 | 39 (80) |
| Chronic obstructive pulmonary disease | 17 | 14 | 31 (63) |
| Lung cancer | 1 | 3 | 4 (8) |
| Prior tuberculosis | 0 | 2 | 2 (4) |
| Recurrent pulmonary infection† | 5 | 2 | 7 (14) |
| Bronchiectasis | 2 | 4 | 6 (12) |
| Smoker, current/ past | 15/ 6 | 11/ 3 | 35 (71) |
| Alcohol abuse | 2 | 3 | 5 (10) |
| High-dose steroid use‡ | 3 | 5 | 8 (16) |
| HIV infection | 2 | 5 | 7 (14) |
| Mean CD4 count in HIV-infected patients, cells/mL | 226 | 126 | 159 |
| Hematologic malignancy | 0 | 1 | 1 (2) |
| Otherwise impaired immunity§ |
2 |
1 |
3 (6) |
| Signs and symptoms | |||
| Productive cough | 21 | 20 | 41 (84) |
| Hemoptysis | 5 | 4 | 9 (18) |
| Dyspnea | 14 | 9 | 23 (47) |
| Fever | 11 | 6 | 17 (35) |
| Weight loss | 12 | 7 | 19 (39) |
| Malaise |
16 |
10 |
26 (53) |
| Chest radiographic abnormalities | |||
| Infiltrate | 15 | 12 | 27 (55) |
| Cavity | 12¶ | 3 | 15 (31) |
| Pleural thickening | 3 | 4 | 7 (14) |
| Emphysema | 9 | 9 | 18 (37) |
| Space-occupying lesion | 1 | 3 | 4 (8) |
*ATS+, American Thoracic Society diagnostic criteria for nontuberculous mycobacterialinfection met; ATS–, ATS diagnostic criteria for nontuberculous mycobacterial infection not met.
†>3 requiring treatment in 6 months before primary Mycobacteria xenopi culture.
‡>15 mg prednisone/day for >3 months before primary M. xenopi culture.
§Diabetes mellitus, cisplatinum chemotherapy, anorexia nervosa (all n = 1).
¶Significant association (odds ratio 14.3, 95% confidence interval 2.7–75.6, p = 0.001).
Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.